肺炎不动桿菌治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Acinetobacter Pneumonia Therapeutics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月21日 | 出版商:

Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年全球肺炎不动桿菌治疗市场价值为4.668 亿美元，预计2024 年至2032 年将以6.2% 的复合年增长率强劲增长。流行率不断上升推动的，一种与严重医院获得性感染有关的病原体，特别是在免疫功能低下的患者中。这些感染的发生率不断上升，特别是在重症监护病房（ICU）中，增加了对有效治疗方案的需求，进一步推动了市场成长。

不动桿菌肺炎疗法专注于专门设计用于对抗不动桿菌属（尤其是鲍曼不动桿菌）引起的肺炎的药物和治疗方法。这种类型的肺炎在医院环境中普遍存在，通常对多种抗生素表现出抗药性，使治疗变得复杂。

整个肺炎不动桿菌治疗产业根据药物类别、给药途径、年龄层、配销通路和地区进行分类。

依药物类别，市场分为几个药物类别，包括头孢菌素类、碳青霉烯类、氟喹诺酮类、甘氨酰环素类、B-内酰胺类抗生素、舒巴坦、氨基糖苷类、多粘菌素类、四环素类、磺胺类等。 2023年，头孢菌素细分市场以7,070万美元领先市场。头孢菌素因其广谱活性和对不动桿菌属（包括 MDR 菌株）的有效性而受到青睐。它们的高效、低毒性和多种剂型使其在这一治疗领域占据主导地位。

依给药途径，市场分为肠胃外、口服和吸入途径。 2023 年，肠外给药占据了最大的市场份额，达到 73.1%。这种方法对于重症患者尤其重要，使其成为医院环境中的首选。

按年龄组，市场分为老年、成人和儿科细分市场。老年病领域在 2023 年处于领先地位，预计 2024 年至 2032 年将以 6.1% 的复合年增长率增长。全球老龄化人口的不断增加进一步推动了针对这一人群的专门治疗的需求。

依配销通路划分，市场分为医院药房、零售药房和网路药房。医院药局在 2023 年占据主导地位，预计到 2032 年将达到 4.441 亿美元。它们在管理和分配治疗严重感染的专用抗生素、确保及时、准确地交付药物方面发挥着至关重要的作用。

在北美，不动桿菌肺炎治疗市场2023年价值为2.247亿美元，预计复合年增长率为6.0%。该地区先进的医疗基础设施、医院获得性感染的高发病率以及对研发的大量投资使其在市场中占据主导地位。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

AstraZeneca PLC
Basilea Pharmaceutica Ltd.
Bayer AG
GlaxoSmithKline plc
Johnson and Johnson
Merck and Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.

简介目录

Product Code: 10900

The Global Acinetobacter Pneumonia Therapeutics Market was valued at USD 466.8 million in 2023 and is projected to grow at a robust CAGR of 6.2% from 2024 to 2032. This growth is driven by the increasing prevalence of multidrug-resistant (MDR) strains of Acinetobacter baumannii, a pathogen linked to severe hospital-acquired infections, particularly among immunocompromised patients. The rising incidence of these infections, especially in intensive care units (ICUs), has heightened the demand for effective treatment options, further boosting market growth.

Acinetobacter pneumonia therapeutics focuses on drugs and treatments specifically designed to combat pneumonia caused by Acinetobacter species, especially Acinetobacter baumannii. This type of pneumonia, prevalent in hospital settings, often shows resistance to multiple antibiotics, complicating treatment.

The overall Acinetobacter pneumonia therapeutics industry is categorized based on Drug Class, Route of Administration, Age-group, Distribution Channel, and Region.

By Drug Class, the market is categorized into several drug classes, including cephalosporins, carbapenems, fluoroquinolones, glycylcyclines, B-lactam antibiotics, sulbactam, aminoglycosides, polymyxins, tetracyclines, sulfonamides, and others. In 2023, the cephalosporins segment led the market with USD 70.7 million. Cephalosporins are preferred due to their broad-spectrum activity and effectiveness against Acinetobacter species, including MDR strains. Their high efficacy, low toxicity, and various formulations contribute to their dominance in this therapeutic area.

By Route of Administration, the market is segmented into parenteral, oral, and inhalation routes. Parenteral administration held the largest market share of 73.1% in 2023. This route is favored for severe infections like Acinetobacter pneumonia because it delivers medications directly into the bloodstream for rapid action. This method is especially crucial for critically ill patients, making it the preferred choice in hospital settings.

By Age Group, the market is divided into geriatric, adult, and pediatric segments. The geriatric segment led in 2023 and is expected to grow at a CAGR of 6.1% from 2024 to 2032. The elderly are particularly susceptible to Acinetobacter infections due to age-related immune decline and comorbidities. The rising global aging population further drives the demand for specialized treatments for this demographic.

By Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies dominated in 2023 and are anticipated to reach USD 444.1 million by 2032. They play a crucial role in managing and dispensing specialized antibiotics for severe infections, ensuring timely and accurate delivery of medications.

In North America, the Acinetobacter pneumonia therapeutics market was valued at USD 224.7 million in 2023 and is expected to grow at a CAGR of 6.0%. The region's advanced healthcare infrastructure, high prevalence of hospital-acquired infections, and substantial investments in R&D contribute to its dominant position in the market.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of Acinetobacter infections
  - 3.2.1.2 Advancements in drug development
  - 3.2.1.3 Growing awareness and diagnosis rates
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Side effects and toxicity
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Cephalosporins
5.3 Carbapenem
5.4 Fluoroquinolone
5.5 Glycylcycline
5.6 B-Lactam antibiotics
5.7 Sulbactam
5.8 Aminoglycoside
5.9 Polymyxins
5.10 Tetracycline
5.11 Sulfonamide
5.12 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Parenteral
6.3 Oral
6.4 Inhalation

Chapter 7 Market Estimates and Forecast, By Age-group, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Geriatric
7.3 Adult
7.4 Pediatric

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 The Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa